Agilent Technologies acquires specific assets of A2 Technologies Agilent Systems Inc.
Agilent Technologies acquires specific assets of A2 Technologies Agilent Systems Inc. Financial details were not disclosed for the acquisition, that was announced Jan first les effets secondaires des médicaments sur ordonnance . 19. The acquisition supports Agilent’s goal of growing its spectroscopy business. Substantially most of A2 Technologies’ intellectual real estate, technology and spectroscopy item portfolio are now component of Agilent’s Spectroscopy Solutions Division within its Chemical Analysis Group. All previous A2 Technologies workers have joined Agilent.
Helen Cox and Cheryl McDermid of Medecins Sans Frontieres in an accompanying commentary stated that intense treatment [of XDR-TB] is the logical strategy to supply the best chance of [treatment success] while preventing the creation of additional drug resistance, but added that researchers should be cautious in [their] desire to attain such success rates in configurations with a higher prevalence of HIV . An abstract of the study online is available. This article is certainly republished with kind permission from our close friends at The Kaiser Family Foundation. You can view the complete Kaiser Daily Health Plan Record, search the archives, or sign up for email delivery of in-depth coverage of wellness policy developments, discussions and debates.